Nippon Shinyaku Overview
- Year Founded
-
1919
- Status
-
Public
- Employees
-
2,309
- Stock Symbol
-
4516
- Investments
-
3
- Share Price
-
$21.24
- (As of Friday Closing)
Nippon Shinyaku General Information
Description
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
Contact Information
Website
www.nippon-shinyaku.co.jpCorporate Office
- 14, Nishinosho-Monguchi-cho
- Kisshoin, Minami-ku
- Kyoto, 601-8550
- Japan
Corporate Office
- 14, Nishinosho-Monguchi-cho
- Kisshoin, Minami-ku
- Kyoto, 601-8550
- Japan
Nippon Shinyaku Stock Performance
As of 13-Nov-2026, Nippon Shinyaku’s stock price is $21.24. Its current market cap is $1.43B with 67.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.24 | $21.40 | $20.64 - $42.03 | $1.43B | 67.4M | 400K | $2.77 |
Nippon Shinyaku Financials Summary
As of 30-Sep-2026, Nippon Shinyaku has a trailing 12-month revenue of $1.2B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,014,801 | 1,779,179 | 1,328,927 | 1,566,454 |
| Revenue | 1,200,594 | 1,132,998 | 1,050,715 | 1,026,058 |
| EBITDA | 268,223 | 279,483 | 271,905 | 265,195 |
| Net Income | 187,014 | 197,187 | 213,498 | 178,912 |
| Total Assets | 2,133,773 | 2,166,667 | 1,895,433 | 1,740,363 |
| Total Debt | 21,135 | 16,058 | 18,190 | 18,976 |
Nippon Shinyaku Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nippon Shinyaku Patents
Nippon Shinyaku Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7904973-B1 | Collagen odor improving agent, collagen odor improving method, and composition containing nmn and collagen | Active | 18-Nov-2025 | ||
| JP-7742516-B1 | Treatment for eosinophilic granulomatosis with polyangiitis | Active | 31-Jul-2025 | ||
| WO-2026205149-A1 | Azaindole compound and salt thereof, and crystal of said compound or said salt, method for synthesizing said compound, said salt or said crystal, synthetic intermediate, and medicine | Pending | 26-Mar-2025 | ||
| JP-2026147876-A | Garcinia extract-containing composition, method for reducing body fat | Pending | 07-Mar-2025 | ||
| WO-2026141349-A1 | Azaindole compounds and intermediate for synthesizing same, method for synthesizing these, and pharmaceutical | Pending | 24-Dec-2024 |
Nippon Shinyaku Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nippon Shinyaku Investments (3)
Nippon Shinyaku’s most recent deal was a IPO with Neo-Precision Therapeutics. The deal was made on 30-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neo-Precision Therapeutics | 30-Jan-2025 | IPO | Drug Discovery | ||
| Capricor Therapeutics | 24-Sep-2024 | PIPE | Biotechnology | ||
| Jazz Pharmaceuticals (NS-73 License) | 30-Mar-2017 | Corporate Asset Purchase | Buildings and Property |
Nippon Shinyaku ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
28.71 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Nippon Shinyaku Exits (1)
Nippon Shinyaku’s most recent exit was on 24-Sep-2024 from Capricor Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Capricor Therapeutics | 24-Sep-2024 | Completed |
|
Nippon Shinyaku Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Nippon Shinyaku Advance Co. | Kyoto, Japan | 1962 | |
| Tajima Shokuhin Kogyo Kk | Toyoka, Japan | 1948 | |
| Sioe Pharmaceutical Co. | Amagasaki, Japan | 1879 |
Nippon Shinyaku FAQs
-
When was Nippon Shinyaku founded?
Nippon Shinyaku was founded in 1919.
-
Where is Nippon Shinyaku headquartered?
Nippon Shinyaku is headquartered in Kyoto, Japan.
-
What is the size of Nippon Shinyaku?
Nippon Shinyaku has 2,309 total employees.
-
What industry is Nippon Shinyaku in?
Nippon Shinyaku’s primary industry is Pharmaceuticals.
-
Is Nippon Shinyaku a private or public company?
Nippon Shinyaku is a Public company.
-
What is Nippon Shinyaku’s stock symbol?
The ticker symbol for Nippon Shinyaku is 4516.
-
What is the current stock price of Nippon Shinyaku?
As of 13-Nov-2026 the stock price of Nippon Shinyaku is $21.24.
-
What is the current market cap of Nippon Shinyaku?
The current market capitalization of Nippon Shinyaku is $1.43B.
-
What is Nippon Shinyaku’s current revenue?
The trailing twelve month revenue for Nippon Shinyaku is $1.2B.
-
What is Nippon Shinyaku’s annual earnings per share (EPS)?
Nippon Shinyaku’s EPS for 12 months was $2.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
